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Abstract
Despite past 60 years of extensive research in antileishmanial drug development, the suc-
cessful therapy of this disease cannot be achieved at full potential. The biological barriers 
encountered by the therapeutic modalities favor the disseminations of the disease like 
intramacrophage location of parasite, lack of oral bioavailability, permeability across the 
cutaneous tissue, and active efflux of the drug. Nanomedicines are specifically engineered 
nano-sized delivery systems. The goal of designing a nanomedicine is to achieve the spe-
cific therapeutic objective via targeting the specific cells and intracellular locations, phar-
macological receptors, enzymes and proteins, crossing biological barriers, and navigation 
through endocytic pathways. This chapter will cover various nanomedicinal approaches 
like targeting the macrophages, pathological organs, efflux pumps, metabolic enzymes, 
redox biology of Leishmania by using polymeric and metal nanocarriers to overcome all the 
biological barriers thus providing a successful alternative over the conventional therapies.
Keywords: biological barriers, macrophage targeting, nanocarriers, photodynamic 
therapy, oral bioavailability, leishmaniasis
1. Introduction
The challenges faced by the current antileishmanial therapy include subtherapeutic efficacy, 
development of resistance, toxicity, and cost-effectiveness [1]. Despite past 60 years of exten-
sive research in antileishmanial drug development, the successful therapy of this disease 
cannot be achieved at full potential. There is no vaccine available against Leishmania and the 
treatment relies mainly on the chemotherapy. The classic chemotherapeutic agents cannot 
control the prevalence of Leishmania effectively as they encounter various biological barriers 
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like the intramacrophage location of Leishmania parasite, selective access to the pathological 
organs, lack of oral bioavailability, permeability across the cutaneous tissue, activity of drug 
efflux pumps, development of toxicity and serious side effects. Leishmania parasite utilizes 
these barriers in its favor like redox biology of Leishmania helps them to survive inside the 
phagolysosomes of the macrophages, and impermeability of the macrophages for the anti-
leishmanial drugs deprives the free access of drug to the target [2]. The nontargeted nature 
of current therapeutic modalities results in free circulation of drugs in the blood, and accu-
mulation in the pathological organ at desired concentration cannot be achieved. Permeability 
glycoprotein (P-gp) efflux pumps present in Leishmania actively efflux the drug out of the 
cell resulting in decreased intracellular accumulation [3]. Lack of oral absorption necessitates 
the parental formulation of antileishmania drugs, which needs hospitalization of the patients 
and lack of compliance. These circumstances augment the development of new therapeutic 
option which can be achieved either by developing the new antileishmanial agents or by 
changing the drug delivery systems. Traditional new drug development usually takes over 
10–12 years and involves extensively high manufacturing cost. Leishmaniasis is a neglected 
tropical disease and receives very little funding regarding the research and development due 
to low market turnover [4]. So, switching the research toward the new drug delivery systems 
such as nanomedicine is a suitable approach in pursuit of successful therapy of leishmaniasis.
Nanomedicine is a specifically engineered nano-sized particulate drug delivery system 
designed for the improved pharmaceutical formulations. The nanoparticles can achieve the 
discrete therapeutic objectives which are otherwise impossible with conventional drug deliv-
ery systems like targeting a specific cell and organelles, enzymes, proteins, and pharmaco-
logical receptors, accumulating in the pathological organs, bypassing the organs prone to the 
toxic effects, crossing biological membranes, and navigating through endocytic pathways [5]. 
All these properties of nanoparticles can address the biological barriers encountered in the 
effective therapy of leishmaniasis. Various polymeric and metal nanocarriers-based strategies 
like macrophage targeting, organ targeting, improved oral bioavailability, and photodynamic 
therapy are being explored for their supreme antileishmanial effects.
This chapter will discuss the various biological barriers compromising the effectiveness of 
antileishmanial therapy and the role of nanomedicine to overcome the problems associated 
with the conventional therapeutic modalities thus providing a platform for the enhanced 
antileishmanial therapy.
2. Current medical management of leishmaniasis
For the past six decades, the standard first-line drugs for the treatment of leishmaniasis are 
antimonial drugs, meglumine antimoniate, and sodium stibogluconate [6]. Antimonial com-
pounds required to be administered IV/IM at the dose of 20 mg/kg of Sb-V for 10 days in 
case of cutaneous leishmaniasis (CL) and for 28 days in case of visceral leishmaniasis (VL). 
Antimonial drugs act by inhibiting a thiol metabolic enzyme trypanothione reductase (TR) and 
thus causing a decreased trypanothione (T[SH]
2
) levels which results in the decreased ability 
of the parasite to counteract the oxidative stress [7]. However, the variations in the clinical 
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response and development of resistance from the past several years are a persistent clinical 
threat. The activity of aqua glycoproteins, trypanothione reductase/trypanothione (TR/T[SH]
2
) 
system, and permeability glycoprotein (P-gp) efflux pumps is involved in the development 
of resistance resulting in decreased intracellular accumulation of antimony in subtherapeutic 
concentrations thus jeopardizing the effectiveness [8, 9]. Serious toxic effects associated with 
antimonial therapy like cardiotoxicity, changes in ECG, renal and liver impairment, muscle 
pain, and severe fatigue further limit the therapeutic potential of antimonial compounds [10].
Amphotericin B (AmB), a polyene antibiotic, is the second-line standard drug for the leish-
maniasis since the 1960s [11]. Whereas, in India, the AmB is the first-line drug approved for 
VL due to widespread resistance against antimonial compounds. The standard dose of AmB 
for VL is 1 mg/kg every other day for 20 days via IV route. It has selective activity against the 
Leishmania, Trypanosoma cruzi, and fungi due to the presence of ergosterol in the said microbes 
compared with the mammal cell having cholesterol in their cell membranes. AmB binds with 
the ergosterol and induces pore formation [12]. Moreover, resistance against the AmB is further 
related to the change in cell membrane composition and fluidity. Leishmania donovani-resistant 
strains showed a significant change in the sterol profile, in which the ergosterol was replaced 
by a precursor known as cholesta-5,7,24-trien3β-ol [13, 14]. This is due to the loss in func-
tionality of S-adenosyl-l-methionin-C24Δ-sterol methyltransferase resulting in the impaired 
C-24 transmethylation [15]. The use of AmB results in nephrotoxicity resulting in renal failure, 
thrombocytopenia, anemia, anaphylaxis, convulsions, phlebitis, and high fever [16].
Miltefosine (MILT) has been recently tagged as an antileishmanial drug required to be admin-
istered at the dose of 50 mg orally three times a day for 28 days. The variation in the clinical 
response has been observed due to the species variations and the development of resistance 
[17]. Promastigote-resistant strains of L. donovani have been developed in the laboratory that 
was resistant against the MILT up to 40 μM [18]. The mechanism of resistance was found to be 
greater than 95% of reduced accumulation indicated by the 14C-labeled MILT. Pérez-Victoria 
et al. [19] reported the involvement of novel plasma membrane P-type transporters from the 
aminophospholipid translocase subfamily to be responsible for the reduced accumulation of 
glycerophospholipid and MILT in the resistant promastigotes [19].
Pentamidine (PTM) is also being used as the second-line therapy against leishmaniasis; how-
ever, the use is limited in zoonotic settings. The recommended dose is 2–3 mg/kg, IV or IM 
once a day for 4–7 doses in case of CL, while for VL, its dose is 2–4 mg/kg administered 
every other day via IV or IM for up to 15 doses. The use of PTM in the pentavalent antimo-
nial Sb(V) refractory patients in India resulted in decreased efficacy from 95 to 70% within a 
short duration suggesting the development of resistant against the PTM. Resistance to PTM in 
Leishmania is due to the inhibition of polyamine biosynthetic, and studies suggested that PMT 
is transported into the cell via polyamine and arginine transporters [20].
From above discussion, it is evident that resistance against the antileishmanial agents is ris-
ing, compromising the therapeutic efficacy. Apart from the development of resistance, other 
factors like associated toxic effects, unavailability of oral dosage forms, longer duration of 
therapy, and high cost also contributing toward the suboptimal control of leishmaniasis. 
These limitations arise primarily due to the various biological barriers encountered by the 
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Figure 1. Endocytosis of Leishmania parasite and macrophage-induced oxidative burst.
antileishmanial agents. Considering the development of parasitic resistance and a limited 
number of effective antileishmanial drugs, there is an imperative demand to revise the stan-
dard medical management of leishmaniasis. Administering the available standard drugs with 
appropriate delivery systems that help to cross the biological barriers seems to be an encour-
aging strategy, which requires being given serious consideration.
3. Biological barriers to leishmaniasis therapy
3.1. Intramacrophage location
Mononuclear phagocytes (MP; monocytes, macrophages, and dendritic cells) along with 
eosinophils and neutrophils constitute the first line of defense against the invading pathogens 
and are involved in detection and elimination of the foreign bodies [21]. When the sand fly 
takes the blood meal, it inoculates the promastigotes of Leishmania along with saliva. The saliva 
contains immunogenic proteins that trigger the immune response. The promastigotes are 
immediately taken up by the MP cells like macrophages following a receptor-mediated endo-
cytic event. During initial recognition, the macrophage receptors play a vital role depending 
upon the Leishmania species like scavenger receptors (SRs), mannose receptors (MRs), comple-
ment receptors (CRs), and fibronectin receptors (FRs). The binding of the parasite to specific 
receptors then determines the course of infection [22]. Upon the successful entrapment of 
Leishmania inside macrophages, complex cellular signals are produced like activation of lyso-
somal enzymes, production of nitric oxide (NO•), and initiation of oxidative burst as shown in 
Figure 1 [23, 24]. Oxidative burst is a potent antileishmanial response produced by the reactive 
oxygen species (ROS) namely hydroxyl ion (OH−), hydrogen peroxide (H
2
O
2
), peroxynitrite 
(ONOO−), and hypochlorous acid (HOCI) [25]. Leishmania employs the various mechanisms 
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to counteract the ROS-like activation of protein tyrosine phosphatase (PTP) and TR/T[SH]
2
 
system [26, 27]. Thus, Leishmania parasite survives the oxidative stress induced by the macro-
phages owing to its unique redox biology where it replicates and utilizes macrophages as a 
source of propagation of infection. The macrophage cell membrane is not freely permeable to 
the antileishmanial agents and acts as a barrier against the intracellular accumulation of che-
motherapeutic agents at the concentrations required for optimum therapeutic effectiveness.
3.2. Activity of P-gp efflux pumps
The activity of P-gp efflux pumps presents another major barrier to the antileishmanial therapy 
[28]. Active efflux of the drug via the efflux pumps is one of the most common mechanisms 
for developing multidrug resistance (MDR) in the microorganism [29]. In fact, MDR mediated 
through efflux pumps has been described in various organisms like fungi, bacteria, and pro-
tozoa including Leishmania [30]. P-gp efflux pumps belong to the ATP-binding cassette (ABC) 
transporters, acting as the physiological barrier by extruding the toxins and xenobiotics out 
of the cells. The ABC transporters are the largest superfamily of efflux pumps known; being 
present in all organisms, from archaebacteria to higher eukaryotes. Various types of drugs with 
a wide range of chemical structure can be recognized by a single P-gp molecule ranging in 
molecular weight from 250 g/mol (cimetidine) to 1202 g/mol (cyclosporine). P-gp is primarily 
found in epithelial cells which have the excretory roles including the apical surface of epithelial 
cells lining the colon, small intestine, where it is involved in the decreased oral bioavailability 
of drugs [31]. In Leishmania, two types of ABC transporter have been reported to be amplified in 
the laboratory strains when exposed to different drugs: P-gp and multidrug resistance-related 
protein (MRP) also known as P-gp A [32]. P-gp A is believed to be involved in the decreased 
intracellular accumulation of antimonial compounds, the first-line therapy against Leishmania, 
resulting in the subtherapeutic response and emergence of resistance. The gene responsible for 
the P-gp A has been found to be amplified in the laboratory mutant strains of Leishmania that 
were resistant to the antimonial compounds [33]. However, this transporter is not involved 
in the efflux of antimonial drugs in the form of Sb-III or SB-V rather it confers resistance by 
sequestration of Sb-III conjugated with T[SH]
2
 in the form of Sb-III-T[SH]
2
 adducts as presented 
in Figure 2 [34]. T[SH]
2
 acts as the main reducing agent and is oxidized into its disulfide form 
T[S]
2
 which is reduced back to T[SH]
2
 by the activity of NADPH-dependent enzyme TR [35]. 
T[SH]
2
 exerts its protective effect by the reduction of NO•, H
2
O
2
, and ONOO−. Sb-V are con-
verted to its trivalent form (Sb-III) inside the cell, and Sb-III has the ability to form a complex 
with the thiol groups of T[SH]
2
. This Sb-III-T[SH]
2
 conjugate is sequestrated by the P-gp A 
pumps. Thus, in Leishmania, the P-gp efflux pumps work in coordination with the activity of 
TR/T[SH]
2
 system resulting in decreased intracellular accumulation of SB-III [36].
3.3. Lack of oral bioavailability
Oral administration is the most suitable method of delivering the drugs due to the convenience 
of dosing, noninvasive nature, and high acceptance at patient levels [37]. Most of the therapeu-
tic agents used for systemic and localized GIT effects are administered orally because of the 
highly absorptive nature of the intestine that provides a large surface of around 300–400 m2. The 
oral administration is successful only in the case where the drugs have sufficient bioavailability. 
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Many physiochemical and physiological factors determine the oral bioavailability of drugs like 
solubility, permeability, a mucus layer, partition coefficient, stability, dissolution, pH, enzymatic 
degradation, and activity of P-gp efflux pumps. Unfortunately, most of the antileishmanial drugs 
encounter the above-described barriers and exhibit limited oral bioavailability except for MILT.
In fact, solubility and permeability govern the oral bioavailability. Most of the drugs diffuse 
across cell membrane via passive transport, and for that purpose, the drug should be lipo-
philic in nature as the unionized form is better to diffuse across the phospholipid bilayer. 
However, the drug molecules should not be lipophilic enough to remain soluble in the lipid 
bilayer suggesting a suitable log P value. To maximize the possibilities of passive diffusion, 
the ideal log P value is considered to be around 2. The molecular weight of the drug also has 
a role in the passive diffusion of the drug and molecular mass less than 500 Da is considered 
to be favorable for the absorption across the small intestine [38]. The effect of solubility, per-
meability, and molecular weight is better explained in Lipinski’ s rule. Lipinski’s rule of five 
is a very useful tool to predict the drug-like characteristics of a compound and is especially 
applicable to assess whether a drug is orally active or not [39]. Lipinski’s rule states that in 
general, an orally active drug has no more than one violation of the following criteria:
• No more than five hydrogen bond donors (the total number of nitrogen-hydrogen and 
oxygen-hydrogen bonds);
• No more than 10 hydrogen bond acceptors (all nitrogen or oxygen atoms);
• A molecular mass less than 500 Da;
• An octanol-water partition coefficient log P not greater than 5.
Most of the antileishmanial drugs do not follow the Lipinski’s rule of five, therefore, not absorbed 
orally. According to biopharmaceutics classification system (BCS), AmB is class IV drug with the 
Figure 2. Mechanism of P-gp efflux pumps and TR-mediated drug resistance against antimonial compounds. ORN = 
ornithine, ODC = ornithine decarboxylase, GS = glutathione synthetase, Cys = cysteine, and Gly = glycine.
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aqueous solubility of <1 mg/L at physiological pH, molecular weight of 924 Da, and log P of 0.95, 
17 hydrogen bond acceptors and 12 hydrogen bond donors and in this way does not follow the 
rule of 5. Similarly, sodium stibogluconate possesses a molecular weight of 910.10 Da and log P 
of −0.34, 17 hydrogen bond acceptors, and 5 hydrogen bond donors, thus violate the rule of 5. 
The physiochemical properties of the antileishmanial drugs are presented in Table 1.
Thus, the lack of oral bioavailability of most of the antileishmanial agents is the major limi-
tation in the cost-effective and optimum therapy of leishmaniasis. Minimal oral absorption 
below the minimum effective concentration (MEC) necessitates the formulation of antileish-
manial drugs for the parenteral administration. The long-term parenteral administration has 
its own limitations as it requires the patient to be hospitalized, increased cost of the therapy, 
and patient compliance.
3.4. Skin as barrier to topical therapy
Skin is the largest organ of the body and protects the organism from the external environment. 
Histologically, the skin is divided into the superficial layer called the epidermis and a deeper 
layer, the dermis. The several strata make up the epidermis distinguished by the changes in 
keratinocytes from dermis-epidermis junction to the outer surface of epidermis, the stratum 
corneum (SC). SC is designated as the main barrier to the transport of substances across the 
skin and is formed by the corneocytes characterized as densely packed, dead, and keratinized 
cells. These cells are surrounded by the intracellular lipid matrix composed of nonpolar lipids 
in lamellar lipid layers, making SC a hydrophobic layer [40]. Although SC is only 10–20 μm in 
thickness, it acts a barrier and hampers the penetration of microorganisms, drugs, and other 
chemicals besides being involved in the transepidermal water loss.
Drug delivery across the skin follows three possible pathways: the intracellular route, between 
the corneocytes sinuously through the lipid layer; the transcellular route, through the corneo-
cytes and lipid matrix; and through the cutaneous appendices (sweat and sebaceous glands, 
hair follicles). The drug diffusion across the skin is essentially a passive transport; however, 
it follows either one or combination of the three pathways. However, it must be noted that 
the intracellular route is considered to be the most suitable for the drug diffusion as it offers 
less resistance compared to the transcellular route in which the drug molecules have to move 
Drug Molecular weight 
(Da)
Log P Hydrogen acceptor Hydrogen donor Rule of five
Sodium stibogluconate 907.88 −3.4 17 5 No
Amphotericin B 924.079 −0.66 17 12 No
Paromomycin 615.62 −8.3 19 13 No
Pentamidine 340.41 2.32 6 4 Yes
Miltefosine 407.57 2.25 2 0 Yes
Table 1. Physicochemical properties of antileishmanial agents.
Crossing Biological Barriers for Leishmaniasis Therapy: From Nanomedicinal Targeting Perspective
http://dx.doi.org/10.5772/intechopen.75911
205
between the intercellular hydrophobic region to intracellular hydrophilic region repeatedly. 
The skin appendages, although having a small surface area compared to the total skin (0.1%), 
present an opportunity for the penetration of ions, polar compounds, and large molecules 
and thus circumvent the low diffusional character of SC [41].
To deliver the drug across the skin, the choice of the adequate molecule in terms of molecular 
weight and partition coefficient is very important. A molecular weight less than 600 Da, low 
melting point, and suitable log P are desired. Thus, the drug with high molecular weight and 
hydrophilic character will face the maximum resistance and their penetration will be limited 
[40]. The drugs for the CL-like paromomycin (PA), antimonial compounds, face the problem 
of skin penetration due to their hydrophilicity and high molecular weight. In case of CL, 
the lesions are developed and parts of epidermis and dermis are lost; therefore, the barriers 
provided by the SC are absent and almost any type of drug can be absorbed. However, the 
formation of scar tissues and keratotic nodules during the healing process restores the func-
tionality of SC thus depriving the drug absorption at the end of the treatment, and complete 
healing of the lesion is difficult [42].
4. Nanodrug delivery system for leishmaniasis
The drug delivery systems are crucial in drug development and design, and many active phar-
maceutical ingredients result in serious side effects when administered nonspecifically. The 
lack of appropriate drug delivery system causes the therapeutic modalities to be accumulated 
in healthy tissue inciting the adverse effects, lower bioavailability, and inefficient targeting 
of the desired pathological organs. Most of the latest researches in the field of leishmani-
asis are focused on addressing the physiological, biological, and biopharmaceutical aspects 
of the use of nanotechnology. Nanodrug delivery systems provide an attractive opportunity 
to resolve the drug delivery problems associated with the therapy of leishmaniasis by cross-
ing the above-demonstrated barriers encountered by the antileishmanial drugs. Examples of 
nanotechnology progress in pharmaceutical products include liposomes [43], niosomes [44], 
nanodisks [45], nanoemulsions [46], polymeric nanoparticles [47], solid lipid nanoparticles, 
and polymer-drug conjugates [48] as described in Table 2.
4.1. Liposomes
Liposomes are the lipid bilayer systems described in 1965 and rapidly taken as drug delivery 
systems [49]. In 1977, Ward and Hanson, first time reported the encapsulation of Sb-V into 
liposomes for targeted delivery to liver and spleen in VL. After intravenous administration, 
the Sb levels of liver and spleen were found to be 20-fold higher compared to the free drugs 
[50]. However, due to the toxic effects in monkeys, the interest in liposomal Sb-V was declined 
[51]. The same concept was also applied to AmB in order to avoid its toxicity by encapsulating 
into multilamellar liposomes. The liposomal AmB got a little bit more attention than Sb-V and 
initiated model for the development of three-lipid-based AmB drug delivery systems licensed 
for clinical use (Ambisome®, Amphocil®, and Abelcet®) [52]. However, the only true liposomal 
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formulation, Ambisome®, is recommended for treating patients with leishmaniasis who are 
resistant to antimonials. The efficacy of liposomal AmB was further enhanced by decorat-
ing the liposomal surface with specific ligands like polysaccharides, peptides, antibodies, 
and glycolipids. The decorated liposomes were able to specifically target the macrophages 
to avoid the exposure of AmB to healthy tissues [53, 54]. The detail of macrophage-targeted 
liposomes will be discussed under the section macrophage targeting.
4.2. Niosomes
Niosomes are the attractive alternatives over liposomes due to their increased stability, low 
cost, and biodegradability [55, 56]. Niosomes are the vesicles consisting of nonionic surfac-
tants. Niosomal formulations of sodium stibogluconate were more efficacious compared to the 
liposomes and free drugs against experimental murine VL [56]. More recently, in vivo stud-
ies demonstrated that the niosomes containing autoclaved L. major have a significant result in 
the prevention of CL in BALB/c mice [57]. Niosomes have also found their role in vaccination 
against leishmaniasis. Purified gp63 entrapped into niosomal formulation provided considerable 
resistance to the leishmaniasis when used as the subcutaneous vaccine in C57BL/10 mice [58]. 
Advancement of a commercial antiparasitic vaccine for the human appliance is a central goal that 
faces modern science. Therefore, further research will be required to investigate immunological 
pathways, followed after vaccination with Leishmania antigens loaded into niosomes, and possi-
ble unwanted adverse effects in order to assess the real potential for a vaccination trial in humans.
Type of 
nanocarrier
Active moiety Targeting 
approach
Strain tested Model Ref
Thiolated 
chitosan NPs
Amphotericin B Macrophage 
targeting
L. donovani J774.1 macrophages/BALB/c 
mice
[69]
Chitosan NPs Rifampicin — [71]
Nanocapsules Doxorubicin Wistar rats [72]
Gelatin 
nanoparticles
Amphotericin B L. donovani J774.1 macrophages/
Hamster
[73]
Liposomes Antimony L. chagasi Peritoneal macrophages [74]
GCPQ chitosan Amphotericin B Organ targeting via 
oral route
L. donovani [76]
MT-chitosan Amphotericin B L. donovani J774.1 macrophages/BALB/c 
mice
—
Liposomes Zinc phthalocyanine Photodynamic 
therapy
L. braziliensis [86]
Metal oxide ZnO L. tropica 
KHW23
[87]
Liposomes Paromomycin Skin permeating 
nanocarriers
L. major BALB/c mice [90]
SLN Amphotericin B L. major [92]
Table 2. Various types of nanocarriers and different targeting approaches for leishmaniasis.
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4.3. Polymeric nanoparticles
Polymeric nanoparticles are very valuable in the treatment of infectious diseases like leish-
maniasis owing to the small size and abilities to enhance the cellular uptake, cross the bio-
logical barriers, and deliver drugs at the site of infection [59, 60]. The use of polymer for the 
development of nanocarriers provides us the opportunity of modifying the functional groups 
with various chemical methods to incorporate the desired ligands for better penetration and 
enhanced endocytosis by the active or passive targeting. The ability of polymeric nanocar-
riers to bear the physiological strains and tunable surface properties provides an edge over 
liposomes and niosomes. While utilizing the polymeric nanoparticles for leishmaniasis, the 
category of polymers is of considerable importance as the hydrophobicity of the polymer will 
facilitate the internalization by macrophages, the core target in leishmaniasis. For example, 
polymethylmethacrylate-based nanoparticles indicated a superior macrophage uptake com-
pared to the polycyanoacrylate [61]. Various studies reported the potential of polymeric nano-
carriers in leishmaniasis. Primaquine-loaded polymeric nanoparticles were found to be 21-fold 
more efficient compared to the free primaquine [62]. β-aescin-loaded polylactide-co-glycolide 
nanoparticles showed twofold increase in efficacy against J744.1 macrophage-infected L. 
donovani model [63]. In a recent study, PEGylated polylactic acid nanoparticles loaded with 
bisnaphthalimidopropyl derivatives have been tested against human macrophage and THP-1 
murine J744 macrophage model of leishmaniasis [64].
4.4. Polymer drug conjugate
The advances in the field of polymer engineering have opened new dimensions for the drug 
delivery. One example is the polymer therapeutics in which the drug molecules are attached 
to the polymer backbone by using a suitable chemical method. In this way, the efficacy of the 
drug can be increased significantly with the reduction in the toxicity. The hydrophobic drug 
encounters a problem of free circulation in the blood. The hydrophilicity of these drugs can 
be increased by conjugation of these hydrophobic drugs with the hydrophilic polymer. These 
polymer-drug conjugates provide increased plasma half-life and retention in the infectious tis-
sue with the minimum toxicity. The conjugation of AmB with the N-2-(hydroxypropyl) meth-
acrylamide resulted in the increased efficacy as compared to the free drug (fungizone) [65].
4.5. Nanodisks
Nanometer scale, a lipoprotein-stabilized phospholipid bilayer disk complexes termed 
nanodisks (NDs) are novel transport vehicles different from liposomes because they do not 
hold an aqueous core and are completely soluble in aqueous phase media [66]. NDs harboring 
poorly soluble antileishmanial agent AmB-nanodisks demonstrate an effective therapy for 
experimental CL (L. major) infection in BALB/c mice. Surprisingly, AmB-nanodisks were illus-
trated to have a long-term effect in that parasite burden continued to decrease for more than 
100 days subsequent the final treatment. The results shown for intraperitoneal administration 
are most likely because of the small size of the ND [45].
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5. Nanomedicinal targeting approaches for leishmaniasis
Paul Ehrlich in 1891 was the first to theorize the concept of “magic bullets” providing the first 
description of drug targeting paradigm. The aim of drug targeting is delivering the drug at 
the right concentration at the right time and at the right place. The evolution of this “magic 
bullet” concept revolutionized the drug delivery systems and provided a vast platform, 
known as nanomedicine, to achieve the very specific and highly desirable therapeutic out-
comes that are otherwise impossible to achieve with conventional drug delivery systems [67]. 
Their small size at nanoscale dictates the very unique properties like the interaction with the 
biological entities, penetration across the membrane, intracellular trafficking, accumulation 
at the target area, improved blood circulation, and biodistribution. For example, in case of 
VL, the major organs representing the parasitic burden are liver, spleen, and bone marrow, 
and the drug has to target the parasite inside the macrophage in these organs [68]. In CL, the 
drug must reach the parasite inside the macrophages at the inner layers of skin by crossing 
the skin barrier, SC. To maximize the potential of nanocarriers, a suitable strategy is required 
to target the pathological area via a patient-friendly route of administration while avoiding 
the healthy tissues. In view of this, various nanomedicinal targeting approaches have been 
explored for the therapy of leishmaniasis like macrophage targeting, organ targeting via the 
oral route, use of permeability enhancers, and photodynamic therapy (PDT).
5.1. Macrophage-targeted drug delivery
The niche in which Leishmania parasite lives presents challenges to drug delivery, and depend-
ing upon the species and the area affected, the drug has to achieve antiparasitic levels at mul-
tiple sites. Furthermore, the antileishmanial drug has to cross the multiple membranes before 
they act on the parasite. Nanoparticle-mediated drug delivery system to overcome the cell 
membrane barriers, release the drug inside the cells, and specifically target Leishmania-infected 
macrophages is emerged as a promising strategy to overcome resistance [69]. Various phago-
cytic receptors are expressed on the surface of Leishmania like MRs, CRs, SRs, and FRs [22]. These 
receptors bind with the specific ligands on the surface of Leishmania parasite and internalize the 
parasite. MRs are highly expressed especially on the Leishmania-infected macrophages. MRs 
recognize and bind with mannose and fructose glycoproteins followed by rapid endocytosis 
of the parasite. The mannose-binding protein belongs to the lectin-like carbohydrate-binding 
groups and cytoplasmic group that are involved in the remodeling of the cytoskeleton during 
endocytosis [2]. Scavenger receptors are the glycoproteins and are responsible for recognizing 
a broad range of ligands like chemically modified proteins, the apoptotic cell, low-density 
lipoproteins, phosphatidylserine, and various polyanionic molecules [70].
Targeting the macrophages via these receptors with surface-decorated nanocarriers leads to the 
accumulation of appreciable amounts of drug at the same niche where the parasite resides inside 
the macrophages. Various studies conducted on the macrophage-targeted drug delivery are 
summarized in Table 2. Recently, our research group utilized the MRs for macrophage-targeted 
delivery of mannose-anchored thiolated nanocarriers loaded with AmB. The uptake studies by 
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using the J744.1 macrophages indicated that macrophage-targeted nanocarriers provided AmB 
concentration of 28.6 ± 1.4 μg/106 cells as compared to 0.4 ± 0.01 μg/106 cells of the free AmB. These 
results provided the evidence that macrophage-targeted nanocarriers were 71-fold more efficient 
than the nontargeted ones. Also, the macrophage-targeted nanocarriers were having superior 
antileishmanial activities against L. donovani-infected macrophage model with 13-fold reduced 
IC
50
 values compared to the nontargeted ones. In vivo efficacy studies against L. donovani-infected 
BALB/c mice model at the dose of 1 mg/kg indicated that mannose-bearing thiolated chitosan 
(MTC) nanocarriers were significantly more effective in reducing the parasitic burden (89 ± 7%) 
against the free AmB (17 ± 4%) [69]. In another study, Chaubey and Mishra [71] also targeted 
the macrophages via mannose-decorated chitosan for the delivery of rifampicin against VL. Ex 
vivo cellular uptake studies indicated 16-fold increased uptake in case of mannosylated chitosan 
nanoparticles (mCNPs). The pharmacokinetic studies revealed that mCNPs exhibited Cmax of 
5.40 ± 1.64 μg/ml with MRT of 58.48 ± 9.1 h compared to Cmax of 279.00 ± 17.71 μg/ml and MRT 
of 1.82 ± 0.2 h for free rifampicin indicating the long circulating time of the mCNPs. Similarly, 
very encouraging results were obtained with in vivo biodistribution studies conducted at the 
dose of 12 mg/kg. The maximum accumulation of drug was observed in liver (57.5 ± 1.3%) fol-
lowed by spleen (14.2 ± 1.5%), achieved with mCNPs when compared with the free rifampicin 
(6.91 ± 1.3% for liver and 1.1 ± 0.2% for spleen) after 6 h. The drug accumulation is attributed to 
the fact that macrophage-targeted nanocarriers were rapidly taken up by the MP cells and deliv-
ered to the liver, main pathological organ of VL [71]. Similarly, curcumin-loaded mannosylated 
chitosan-based nanoparticles were reported to be highly efficacious against the free drug. Their 
study indicated that mannosylated nanoparticles effectively increased the endocytosis with the 
mean residence time of 39.38 h compared with the 0.30 h of free drug solution [68].
Kansal et al. [72] utilized scavenger receptors for the macrophage-targeted delivery of doxorubi-
cin via phosphatidylserine-decorated nanocapsules (PS-NCs-DOX) for the therapy of leishmani-
asis. Flow cytometry analysis indicated 1.75-fold increased uptake of PS-NCs-DOX compared 
with nonmodified nanocarriers (NCs-DOX). PS-NCs-DOX also accumulated in liver and spleen 
at higher concentration against NCs-DOX confirmed via in vivo biodistribution analysis in Wistar 
rats. Highly significant antileishmanial activities were observed in Leishmania-infected hamster 
model. PS-NCs-DOX exhibited 85.23 ± 4.49% inhibition of splenic parasitic burden compared with 
72.88 ± 3.87 and 42.85 ± 2.11% parasite inhibition for NCs-DOX and free DOX, respectively [72]. 
Another study reported the development of 1, 2-diacyl-sn-glycero-3-phospho-l-serine (PS)-coated 
gelatin nanoparticles (GNPs) bearing amphotericin B for the enhanced in vitro in vivo antileish-
manial efficacy in VL. The nanocarriers decorated with 1, 2-diacyl-sn-glycero-3-phospho-l-serine 
(PS-AmB-GNPs) were more efficient in terms of uptake by J774A.1 macrophages analyzed via 
flow cytometry [73]. Also, PS-AmB-GNPs exhibited a very significant reduction in parasitic bur-
den providing 85.3 ± 7.89% inhibition compared to 50.5 ± 5.12% of free AmB in Leishmania-infected 
hamster model. Antimony-loaded liposomes have also been modified with phosphatidylserine 
(Sb-LP) for the enhanced uptake of macrophages via scavenger receptors. Sb-LP was 16-fold more 
effective than free drug against L. chagasi-infected macrophage model [74].
5.2. Organ targeting via oral route
One of the limitations associated with the conventional antileishmanial therapy is the free sys-
temic circulation of the drug and distribution into different body organs including pathological 
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and nonpathological. The exposure of nonpathological organs to the drugs is associated with 
the severe toxicity of the antileishmanial drugs thus limiting its therapeutic potential [17]. In 
this regard, the specific organ targeting is a promising strategy that reduces the toxic effects by 
minimizing the exposure to nondesired organs and improves therapeutic efficacy by increasing 
the drug accumulation at the desired organs. One such example of the nanoliposomal formula-
tion of AmB is Ambisome® for VL, when administered is taken up by MP cells and transported 
to the liver and spleen via passive targeting [52, 75]. Although this strategy greatly improves 
the safety of AmB, the macrophage-targeted nanocarriers described above can be of more 
potential in this regard. The surface modification with the ligands actively targets the infected 
macrophages because of the high expression of endocytic receptors like MRs. However, one 
factor, the parenteral delivery of these systems, limits their wide application and acceptance at 
the patient level due to the hazards and high cost associated with and needs to be addressed 
yet. In pursuit of the solution to this limitation, Serrano et al. [76] provided the concept of 
organ targeting via the oral route and introduced nanomedicine in which nanoparticles were 
taken up by the intestinal epithelia and are transported to liver, spleen, and lungs as shown in 
Figure 3, thus enhancing the bioavailability of these pathological organs of VL and bypassing 
the organs of potential toxicity [76]. This technique utilized specifically engineered polymeric 
excipients with the potential to interact with specific proteins in the intestinal epithelium thus 
enhancing the permeation and absorption of the constituted nanocarriers.
Serrano et al. [76] illustrated this concept by utilizing N-palmitoyl-N-methyl N,N-dimethyl-
N,N,N-trimethyl-6-O-glycol chitosan (GCPQ) nanoparticles loaded with AmB. Such modification 
of chitosan will provide the mucoadhesive character to the nanocarriers. As the mucus is a nega-
tively charged glycoprotein, the positively charged polymer will provide increased electrostatic 
Figure 3. Uptake of nanoparticles via oral route and accumulation in liver, spleen, and lungs.
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interaction and bind with proteins thus better chances to be taken up by the enterocytes. Single-
dose oral pharmacokinetic studies in CD-1 mice were carried out by utilizing AmB-GCPQ, 
Amb-sodium deoxycholate (Amb-d), and AmB in dextrose solution at the dose of 5 mg/kg. The 
nanoparticulate formulations, AmB-GCPQ, and Amb-d exhibited higher plasma drug levels com-
pared to the AmB in dextrose. These results indicate that the particulate formulations were able 
to cross the intestinal membrane. Furthermore, significantly higher levels of Amb-GCPQ were 
found in target organs, i.e., liver and spleen as compared to the Amb-d. The target organ to kidney 
ratio was also determined and provided very encouraging results. As AmB is a nephrotoxic drug, 
target organ:kidney ratios are crucial. Lung:kidney AUC0-24 ratios for AmB-GCPQ and Amb-d 
were 1.44 and 0.86, respectively, while the corresponding spleen:kidney ratios were 1.22 and 0.81, 
respectively, and the corresponding liver:kidney ratios were 0.88 and 0.40, respectively. These data 
demonstrate that when compared to the deoxycholate micelles, GCPQ nanoparticles delivered 
relatively more drug to the target organs (liver, lung, and spleen) rather than kidney. These find-
ings were also supported by the low urinary excretion of Amb-GCPQ, while AmB in dextrose 
delivered most of the drug to the kidney, a fact that contributes to the nephrotoxicity associated 
with AmB and reduced drug levels in target organs. Also, the oral particle location to major organs 
was studied by coherent anti-Stokes Raman spectroscopy. The results located the GCPQ nanocar-
riers within the hepatocytes in the liver, intracellular spaces in the hepatocytes. The reason for their 
location in the hepatocytes and lungs is their uptake by the intestinal villi from where they are 
transported to the liver via the hepatic portal vein. GCPQ nanocarriers were also taken up by the 
M cells of Peyer’s patches from where they are carried to the systemic circulation via the lymphatic 
system. The in vivo efficacy studies were carried out in VL murine model. The data indicated oral 
GCPQ nanocarriers were equal in efficacy to the parenterally administered AmB [76].
Recently, our research group utilized thiolated polymer-based mannose-anchored nanocarri-
ers to target the visceral organs via oral route for the delivery of AmB against VL (unpublished 
data). Thiolated polymers, the so-called thiomers, are well known for their mucoadhesion, 
permeation enhancing, and P-gp inhibition properties with great impact on the nanodrug 
delivery. Thiomer contains thiol group (─SH) covalently attached to the polymer chain, and 
by the virtue of –SH, the thiolated polymer can interact with the proteins and receptors via 
disulfide bond formation (─S─S─) in disulfide exchange mechanism [77]. Mucus in the intes-
tine acts as the physical barrier for the diffusion of drugs across the intestinal membrane. The 
structure of mucus is complex, which arises from the properties of mucins. Mucins are large 
glycoproteins composed of more than 800 amino acids, also containing cysteine- and disulfide-
rich domains. Mucins have long flexible proline, threonine, and serine (PTS) domains that are 
glycosylated. The glycans terminate with negatively charged carboxylic groups. Diffusion in 
the mucus structure depends on the charge of the molecules. Mucus contains pores that are 
200–400 nm in diameter, thus allowing diffusion of many APIs [78, 79]. If APIs are encap-
sulated in nano- or microcarriers, the size of the carrier can preclude diffusion in mucus. 
Thiomer-based nanocarriers will remain adhered to the mucus by making disulfide bond 
with the cysteine-rich units of mucin, and by the virtue of small size of nanocarriers, they can 
easily pass through the pores in the mucus. After crossing the mucus barrier, they are taken 
up by the enterocytes, M-cells of Peyer’s patches and also cross the membrane via paracel-
lular route owing to permeation-enhancing capabilities of thiomers. The primary mechanism 
of the permeation enhancing by thiomers is the inhibition of PTP. The inhibition of PTP is 
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accomplished by the disulfide (─S─S) bond formation by thiomer with cysteine-rich units and 
consequently increased phosphorylation of membrane proteins thus leading to the opening 
of tight junction [80]. Furthermore, the mannose anchoring to the thiolated polymer enables 
the nanoparticles to target the macrophages via mannose receptors. Thus, the combined effect 
of mucoadhesion, permeation enhancing, and macrophage targeting successfully target the 
pathological organs of VL, i.e., liver, spleen, and lungs via the oral route.
5.3. Photodynamic therapy
The survival of Leishmania inside macrophages is dependent upon its unique redox biology that 
neutralizes the ROS produced by the macrophages [81]. PDT targets the redox biology of Leishmania 
by producing the ROS that supersedes neutralizing capabilities of the parasite. The increased ROS 
thus exert the antileishmanial effects by jeopardizing the reducing potential [82]. PDT involves 
the delivery of special drug called photosensitizers (PS) to the infectious tissue with nanocarriers 
and subsequent exposure to a light of specific wavelength. The photosensitizers absorb the light 
and then transfer the energy to the molecular oxygen which is converted to the free oxygen [O•] 
or OH•. These ROS are responsible for the killing of the cells or tissue where the PS is localized. 
The photooxidation of biomolecules changes the structure and functions of cells. The generation 
ROS can be classified into two types of reactions. Type I reactions called electron transfer reactions 
and are responsible for producing various free radicals including highly reactive OH•. The type 
II reaction involves the energy transfer via molecular oxygen leading to the formation [O•] [83]. 
However, the clinical application of PDT is limited to the easily accessible areas where the direct 
exposure of LASER or incoherent light can be provided. Consequently, the PDT finds its appli-
cation in the treatment of CL [84]. The most commonly used photosensitizer against CL is a 
porphyrin precursor, 5-aminolevulinic acid (ALA). ALA is a substrate for heme synthesis and 
its exogenous delivery results in the accumulation of protoporphyrin IX (PpIX). When exposed 
to the light of a suitable wavelength like the red or blue light after some specific intervals, cell 
death occurs due to the apoptosis and necrosis caused by the activated PpIX generating ROS [85]. 
Zinc phthalocyanine (ZnPc) is another commonly used PS for the PDT. However, one major con-
cern with applying the PS to the skin is that they cannot penetrate to the deeper layers of skin 
because of the SC barrier of the skin. Due to which their efficacy at full potential is hampered.
Nanoparticles have been extensively explored to improve the efficacy of PDT against CL, 
due to the ability to penetrate the skin by crossing SC barrier and also protect the PS from 
aggregation and subsequent inactivation. The current PDT against the CL involves the indi-
rect destruction of the parasites either by enhancing the immune response or by killing the 
macrophages. Montanari et al. [86] conducted a study, in which they delivered ZnPc, loaded 
in liposomes, to treat the infection induced by L. braziliensis. They indicated ZnPc alone has 
20% activity against the promastigotes and amastigotes; however, when incorporated into the 
liposomes the antileishmanial activity increased up to 100% for promastigotes and 80% for 
amastigote. Moreover, the penetration studies indicated liposomal ZnPc showed eightfold 
increased penetration and sevenfold increased accumulation of ZnPc into the deeper layers of 
skin as compared to the ZnPc alone. Their study provided the proof that targeted PDT with 
nanocarriers greatly enhances the penetration and accumulation of PS into deeper layers of 
skin thus enhanced antileishmanial efficacy [86].
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Metallic nanoparticles have found their application in the PDT due to their surface localized plas-
mon response, and they enhance the effectiveness of PDT by producing ROS. Also, they are not 
involved in the immune system activation. Several studies have been reported in which the effec-
tiveness of the metal nanoparticles in the PDT has been established. PEGylated silver-doped zinc 
oxide nanoparticles (DSNs) for the PDT of leishmaniasis have been reported by the Nadhman 
et al. [87]. They indicated DSNs were highly efficacious in providing the photodynamic effect 
than nondoped zinc oxide nanocarriers (NDSNs). Doping of zinc oxide with silver enhanced 
the band gap and thus excitation at the visible light source. The IC
50
 of DSNs was in the range 
of 0.009 (±0.0012) to 0.02 μg/ml (±0.0023), while that of NDSN was 0.1 μg/ml (±0.016). The DSNs 
were 10 times more active than the NDSN. Free radical scavenger studies indicated 77–83% cell 
death occurs due to singlet oxygen, while 18–27% due to the production of hydroxyl ions [87].
5.4. Skin-permeating nanocarriers
The role of the skin as barriers to the drug delivery has been discussed above in detail. The 
nanomedicine is a promising strategy to cross the skin barrier since they offer several advan-
tages over the conventional drug delivery systems, and skin permeation and follicular target-
ing are the most significant regarding the topical treatment of CL. The nanoparticles larger 
than 20 nm and lesser than 200 nm can be accumulated in the hair follicles where they are 
retained for longer period of time for up to 10 days, thus providing the continuous supply of 
the drug for the absorption [88, 89]. Various types of nanocarriers have been utilized for this 
purpose but the lipid-based nanocarriers such as liposomes, solid lipid nanoparticles, and 
nanoemulsions are most extensively studied for skin permeation.
Ferriera et al. [90] first time reported the encapsulation of PA into liposomes and evaluated their 
permeation across the stripped and intact mouse skin. The results exhibited significantly increased 
PA penetration into and across the intact skin compared to the PA in solution. However, this 
model was based on the hairless skin and cannot be extrapolated for human due to the presence 
of hairs. Topical treatment of L. major infected BALB/c mice resulted in a decrease in lesion size 
in animals treated with PA-loaded liposomes and free PA gel. However, local relapse, character-
ized by the reappearance of ulcers, occurred faster in animals treated with free PA than in those 
treated with liposomes. These findings suggest that liposomes represent a promising alternative 
for the topical treatment of CL using PA [90]. Jaafari et al. [42] reported the efficacy of liposomes 
loaded with PA at 10 and 15%. Both types of liposomal formulations indicated high retention 
and permeation profile of PA in the mouse skin. These formulations exhibited 3–4 times better 
efficacy against L. major amastigotes compared to simple PA solution. Significant reduction in 
the lesion size and parasitic burden in liver and spleen was observed in L. major-infected BALB/c 
mice with topical PA liposomal formulations compared to the control mice. However, in this 
study, comparison of topical treatment with free PA was not reported [42].
Frankenburg et al. [93] evaluated the effectiveness of AmB-based lipid nanoformulations 
applied topically to L. major experimentally infected mice. The three evaluated formulations 
(Amphocil, Fungizone, and Abelcet) were ineffective when applied topically, except when 
Amphocil and Abelcet were dispersed in 5% ethanol. No relapse was observed during the 
follow-up period after treatment [91]. Subsequently, Amphocil dispersed in 5% ethanol was 
tested in L. major-infected patients in a prospective placebo-controlled study. The results 
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provided the significant reduction in the lesion size against the placebo-treated lesions. This 
treatment exhibited complete healing lesions with no evidence of relapse on follow-up vis-
its [92]. This modality was also used for the topical treatment of an infant patient who had 
not responded to the topical application of a PA ointment, resulting in resolution of the skin 
lesions and absence of local or systemic side effects [93].
6. Conclusion
The conventional therapy of leishmaniasis failed to provide the satisfactory control over the 
progression of disease due to the involvement of certain biological barriers. Leishmania parasite 
resides inside macrophages providing a barrier of macrophage cell membrane permeability 
for the drugs. The activity of P-gp efflux pumps directly related to the decreased intracellular 
accumulation of antimonial compounds. The physiochemical properties of antileishmanial 
drugs limit their oral bioavailability making it necessary to deliver drug via IV route. SC pro-
vides another barrier to delivery of drugs in CL. The biological barriers encountered by the 
chemotherapeutic agents leads to the development of resistance, lack of effectiveness and tox-
icity, thus are the factors jeopardizing the full therapeutic potential of antileishmanial drugs. 
These biological barriers cannot be tackled with the conventional drug delivery systems, and 
lack of therapeutic choices necessitates the development of new drug delivery system with 
the better therapeutic profile. In this area, nanotechnology is a great hope that provided real 
breakthrough over conventional formulations. The nanotechnology-based pharmaceutical 
formulations can easily navigate through the biological barriers and enhance the therapeutic 
effectiveness of antileishmanial drugs. Various types of nanocarriers, like liposomes, nio-
somes, polymeric nanocarriers, and metal oxide nanoparticles provided very encouraging 
results regarding leishmaniasis therapy. One of the very promising aspects of nanotechnology 
is the targeted delivery of nanocarriers to a very specific organ of pathology and avoiding the 
healthy tissues. In this regard, the targeting approaches like receptor-mediated macrophage 
targeting, organ targeting via oral route, photodynamic therapy provided a platform for suc-
cessful therapy of the disease. Various nanotechnology-based formulations of antileishmanial 
drugs are in different phases of clinical trial. However, a lot of efforts from the scientific com-
munity are required to further investigate the targeted delivery of antileishmanial agents to 
translate the nanomedicinal concepts into first-line gold standard therapy.
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